Last reviewed · How we verify

NCT05261165

Effect of a Uterine Manipulator on the Incidence of Lymphovascular Propagation (LVSI) in Treatment of Endometrial Cancer

Completed Last updated 2 March 2022
What this trial tests

trial testing hysterectomy in Endometrial Cancer in 170 participants. Completed in 1 October 2021.

Timeline
1 October 2015
Primary endpoint
1 January 2021
1 October 2021

Quick facts

Lead sponsorF.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica
StatusCompleted
Study typeOBSERVATIONAL
Enrollment170
Start date1 October 2015
Primary completion1 January 2021
Estimated completion1 October 2021
Sites1 location across Slovakia

Drugs / interventions tested

Conditions studied

Sponsor

F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica

Who can join

Eligibility, female only, with Endometrial Cancer or LVSI. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

We retrospectively analyzed data and compared the impact of intrauterine manipulators on incidence of LVSI in endometrial cancer patients treated at our department.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Influence of uterine manipulator use on the incidence of lymphovascular propagation in the treatment of endometrial cancer.
    Hudec B, Dókuš K, Urdzík P, Školka R, et al · · 2023 · cited 2× · PMID 36542513 · DOI 10.1080/13645706.2022.2153342

Verify or expand the search:

Other trials of hysterectomy

Trials testing the same drug.

Other recruiting trials for Endometrial Cancer

Currently open trials in the same condition.

Other F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05261165.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing